FrancophonIA/ELRC3.0 huggingface dataset:
English: 20 x 1 film-coated tablet in alu/alu perforated unit dose blisters.
Estonian: 20 x 1 õhukese polümeerikattega tabletti alu/alu-materjalist perforeeritud üksikannustega blistrites.
English: Tel: +354 535 7000
Estonian: Vistor hf. Tel: +354 535 7000
English: Each film-coated tablet contains 200 mg of fidaxomicin.
Estonian: Üks õhukese polümeerikattega tablett sisaldab 200 mg fidaksomitsiini.
English: In that case, skip the missed dose.
Estonian: Sellisel juhul jätke ununenud annus võtmata.
English: There was very limited accumulation of fidaxomicin or OP-1118 in plasma following administration of 200 mg fidaxomicin every 12 hours for 10 days.
Estonian: 200 mg fidaksomitsiini manustamisel iga 12 tunni järel 10 päeva vältel akumuleerus fidaksomitsiin või OP-1118 plasmasse väga vähesel määral.
English: What DIFICLIR contains
Estonian: Kuidas DIFICLIR välja näeb ja pakendi sisu
English: Fidaxomicin has been shown to inhibit C. difficile sporulation in vitro.
Estonian: In vitro ilmnes fidaksomitsiinil C. difficile'i põhjustatud sporulatsiooni inhibeeriv toime.
English: Pharmacotherapeutic group: Antidiarrheals, intestinal antiinflammatory/antiinfective agents, antibiotics, ATC code: A07AA12
Estonian: Farmakoterapeutiline rühm: kõhulahtisuse-, soolepõletiku- ja sooleinfektsioonivastased ained, antibiootikumid.
English: Polyethylene glycol Lecithin (soy)
Estonian: Polüetüleenglükool Letsitiin (soja-)
English: Due to the limited clinical data in this population, DIFICLIR should be used with caution in patients with moderate to severe hepatic impairment (see sections 4.4 and 5.2).
Estonian: Piiratud kliiniliste andmete tõttu selles rühmas tuleb DIFICLIR'i raske neerukahjustusega patsientidel kasutada ettevaatusega (vt lõigud 4.4 ja 5.2).
English: It interferes with RNA polymerase at a distinct site from that of rifamycins.
Estonian: Ravim mõjutab RNA polümeraasi rifamütsiinidest erinevast asukohast.
English: Not known side effects (frequency cannot be estimated from the available data) − swelling of the face and throat (angioedema), trouble breathing (dyspnea)
Estonian: Teadmata sagedusega kõrvaltoimed (sagedust ei saa hinnata olemasolevate andmete alusel)
English: Nonclinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeat dose toxicity, genotoxicity, and reproductive toxicity.
Estonian: Farmakoloogilise ohutuse, korduvtoksilisuse, genotoksilisuse ja reproduktsioonitoksilisuse mittekliinilised uuringud ei ole näidanud kahjulikku toimet inimesele.
English: Method of administration DIFICLIR is intended for oral use.
Estonian: DIFICLIR on ette nähtud suukaudseks kasutamiseks.
English: DIFICLIR 200 mg film-coated tablets
Estonian: DIFICLIR 200 mg, õhukese polümeerikattega tabletid.
English: België/Belgique/Belgien Astellas Pharma B.V.
Estonian: België/Belgique/Belgien
English: NAME OF THE MEDICINAL PRODUCT DIFICLIR 200 mg film-coated tablets fidaxomicin
Estonian: Pakendi infoleht: teave kasutajale DIFICLIR 200 mg, õhukese polümeerikattega tabletid fidaksomitsiin (Fidaxomicinum)
English: Consideration should be given to official guidelines on the appropriate use of antibacterial agents.
Estonian: Antibakteriaalsete ravimite määramisel ja kasutamisel tuleb järgida kohalikke kehtivaid juhendeid..
English: What DIFICLIR is and what it is used for What you need to know before you take DIFICLIR How to take DIFICLIR
Estonian: Mis ravim on DIFICLIR ja milleks seda kasutatakse Mida on vaja teada enne DIFICLIR'i võtmist Kuidas DIFICLIR'i võtta
English: Breast-feeding
Estonian: Fidaxomicinum
English: Tel: +44 (0) 203 379 8700
Estonian: Astellas Pharma Ltd. Tel: +44 (0) 203 379 8700
English: − clarithromycin (a medicine used to treat chest infections, throat and sinus infections, skin and tissue infections and Helicobacter pylori infections associated with duodenal or stomach ulcer)
Estonian: Sellised ravimid on näiteks: - tsüklosporiin (ravim, millega surutakse alla keha immuunreaktsioone ja mida kasutatakse näiteks pärast elundi või luuüdi siirdamist, psoriaasi ja ekseemi ning reumatoidartriidi ja nefrootilise sündroomi korral) - ketokonasool (seennakkuste ravim) - erütromütsiin (kõrva-, nina-, kurgu-, rindkere- ja nahanakkuste ravim) - klaritromütsiin (rindkere-, kurgu-, põskkoobaste-, naha- ja koenakkuste ning kaksteistsõrmiku või maohaavanditega seotud Helicobacter pylori nakkuste ravim) - verapamiil (kõrge vererõhu ja rindkere valuhoogude vastu ning südameataki järgselt edasiste atakkide vältimiseks kasutatav ravim) - dronedaroon ja amiodaroon (südamerütmiravimid) - dabigatraaneteksilaat (ravim, mida kasutatakse vereklompide tekke vältimiseks puusa- või põlveliigese proteesimisoperatsiooni järel).
English: Nervous system disorders dizziness, headache, dysgeusia
Estonian: Pearinglus, peavalu, düsgeusia
English: Astellas Pharma B.V. Tel: +31 (0)71 5455745
Estonian: Tel: +31 (0)71 5455745
English: PHARMACEUTICAL FORM AND CONTENTS 100 x 1 film-coated tablet.
Estonian: 100 x 1 õhukese polümeerikattega tabletti.
English: If you are breastfeeding ask your doctor or pharmacist for advice before taking this medicine.
Estonian: Kui te imetate, pidage enne selle ravimi kasutamist nõu oma arsti või apteekriga.
English: Astellas Pharma S.p.A. Tel: +39 02 921381
Estonian: Tel: +39 02 921381
English: − bloated feeling, wind (flatulence)
Estonian: − Lööve, sügelus (kihelus).
English: Luxembourg/Luxemburg Astellas Pharma B.V.
Estonian: Astellas Pharma B.V.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 200 mg of fidaxomicin.
Estonian: Üks õhukese polümeerikattega tablett sisaldab 200 mg fidaksomitsiini (Fidaxomicinum).
English: 18 October 2012
Estonian: 18. oktoober 2012
English: The company that applied for authorisation is H. Lundbeck A/S, Denmark.
Estonian: Müügiluba taotles Taani ettevõte H. Lundbeck A/S.
English: It was expected to be available as tablets (20 mg/10 mg).
Estonian: Ravimit kavatseti turustada tablettidena (20 mg / 10 mg).
English: The company did not carry out any new studies in patients with Alzheimer's disease.
Estonian: Ettevõte ei teinud Alzheimeri tõvega patsientidega uusi uuringuid.
English: In addition, the company pooled and analysed the results from the different studies together.
Estonian: Lisaks koondas ettevõte eri uuringute tulemused ja võrdles neid.
English: Therefore, the CHMP was of the opinion that the benefits of Acrescent did not outweigh its risks and recommended that it be refused marketing authorisation.
Estonian: Seetõttu oli inimravimite komitee arvamusel, et Acrescenti kasulikkus ei ole suurem kui sellega kaasnevad riskid, ja soovitas müügiloa andmisest keelduda.
English: The causes of Alzheimer's disease are unknown, but the associated memory loss, disorientation and behavioural symptoms are believed to be due to a disturbance of neurotransmitters in the brain.
Estonian: Alzheimeri tõve tekkepõhjus ei ole teada, kuid kaasnevad mälukaotus, orienteerumishäired ja käitumishäired arvatakse tulenevat aju neurotransmitterite häirest.
English: What is Acrescent?
Estonian: Mis on Acrescent?
English: However, the CHMP considered that the treatment guidelines were not consistent across European countries and the company had not provided enough evidence to support the use of a combination tablet in these patients.
Estonian: Inimravimite komitee märkis siiski, et ravisuunised ei olnud Euroopa riikides ühetaolised ja ettevõte ei olnud esitanud piisavalt tõendavaid andmeid, mis toetaksid nendel patsientidel kombineeritud tablettide kasutamist.
English: One main study involved 404 patients with moderate to severe Alzheimer's disease who were already taking donepezil.
Estonian: Ühes põhiuuringus osales 404 mõõduka kuni raske Alzheimeri tõvega patsienti, kes juba võtsid donepesiili.
English: The effectiveness of the combination treatment was assessed by comparing the patients' performance in cognitive tests and in carrying out daily living activities.
Estonian: Kombinatsioonravi efektiivsust hinnati patsientide tulemuste järgi kognitiivsetes testides ja võimes sooritada tavategevusi.
English: Acrescent is a medicine that contains two active substances, memantine hydrochloride and donepezil hydrochloride.
Estonian: Acrescent on ravim, mis sisaldab kahte toimeainet: memantiinvesinikkloriidi ja donepesiilvesinikkloriidi.
English: Acrescent was expected to be used to treat moderate to moderately severe Alzheimer's disease, in patients who are already taking a daily dose of 20 mg memantine and 10 mg donepezil.
Estonian: Acrescenti kavatseti kasutada mõõduka kuni mõõdukalt raske Alzheimeri tõvega raviks patsientidel, kes juba võtavad ööpäevas 20 mg memantiini ja 10 mg donepesiili.
English: The company informed the CHMP that there are no patients currently included in clinical trials with Acrescent in the European Union.
Estonian: Ettevõte teatas inimravimite komiteele, et Acrescenti kliinilistes uuringutes ei osale praegu Euroopa Liidus ühtegi patsienti.
English: It presented the results of seven main studies, including patients (or a subset of patients) who received memantine and donepezil together.
Estonian: Ettevõte esitas 7 põhiuuringu tulemused, sealhulgas selliste uuringute tulemused, milles patsiendid (või osa patsiente) võtsid memantiini ja donepesiili koos.
English: What consequences does this refusal have for patients in clinical trials?
Estonian: Kuidas mõjutab müügiloa andmisest keeldumine kliinilistes uuringutes osalevaid patsiente?
English: The company also presented information intended to show the use of memantine and donepezil in combination to treat Alzheimer's disease across the European Union, including the available guidelines for treating Alzheimer's disease in different European countries.
Estonian: Ettevõte esitas ka teabe memantiini ja donepesiili koos kasutamise kohta Alzheimeri tõve ravis Euroopa Liidus, sealhulgas Alzheimeri tõve olemasolevate ravisuuniste kohta Euroopa riikides.
English: Acrescent is a combination treatment containing two active substances which are already authorised in the EU to treat the symptoms of Alzheimer's disease.
Estonian: Acrescent on kombinatsioonravim, mille mõlemal toimeainel juba on Euroopa Liidus müügiluba ja mis on näidustatud Alzheimeri tõve sümptomite raviks.
English: By blocking NMDA receptors, memantine helps to reduce the symptoms of Alzheimer's disease.
Estonian: NMDA-retseptoreid blokeerides aitab memantiin Alzheimeri tõve sümptomeid leevendada.
English: However, due to the study design it did not demonstrate a clear benefit of the combination treatment, since it did not include a control arm for patients treated with memantine alone.
Estonian: Samas ei tõendanud uuring ülesehituse tõttu kombinatsioonravi selget kasulikkust, sest uuringus puudus ainult memantiini võtnud patsientide kontrollrühm.
English: The Committee was concerned that the studies presented by the company had negative results except for one main study, in which patients already taking donepezil performed better in cognitive tests and in daily living activities when memantine was added to donepezil treatment.
Estonian: Komitee väljendas ettevaatlikkust, et ettevõtte esitatud uuringutes olid negatiivsed tulemused kõigis peale ühe põhiuuringu, milles varem juba donepesiili võtnud patsientide tulemused kognitiivsetes testides ja suutlikkus sooritada tavategevusi olid paremad pärast memantiini lisamist donepesiiliravile.
English: The CHMP considered that the additional analyses provided by the company did not satisfy these concerns.
Estonian: Inimravimite komitee arvates ei lahendanud ettevõtte esitatud lisaanalüüsid probleemi.
English: What was Acrescent expected to be used for?
Estonian: Milleks kavatseti Acrescenti kasutada?
English: The combination of memantine and donepezil is used in some European countries to treat patients with moderate to moderately severe Alzheimer's disease.
Estonian: Memantiini ja donepesiili kombinatsiooni kasutatakse mõnes Euroopa riigis mõõduka kuni mõõdukalt raske Alzheimeri tõvega patsientide raviks.
English: Memantine works by blocking types of receptor called NMDA receptors, to which the neurotransmitter glutamate normally attaches.
Estonian: Memantiini toime seisneb selles, et ta blokeerib teatud retseptoreid (NMDA-retseptoreid), millele tavaliselt kinnitub glutamaat.
English: The Committee also noted that a published study did not show a significant improvement in patients taking the combination treatment when compared with memantine alone.
Estonian: Inimravimite komitee märkis samuti, et ühes avaldatud uuringus puudus kombinatsioonravimit võtnud patsientide seisundi oluline paranemine ainult memantiini võtnud patsientide seisundiga võrreldes.
English: How is Acrescent expected to work?
Estonian: Milline on Acrescenti eeldatav toime?
English: By slowing down the breakdown of acetylcholine, donepezil helps to reduce the symptoms of Alzheimer's disease.
Estonian: Atsetüülkoliini lagunemist aeglustades aitab donepesiil Alzheimeri tõve sümptomeid leevendada.
English: The effects of adding memantine to donepezil was compared with adding placebo for six months of treatment.
Estonian: Uuringus võrreldi memantiini lisamist donepesiilile platseebo lisamisega donepesiilile 6 ravikuu jooksul.
English: On 18 October 2012, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Acrescent, intended for the treatment of moderate to moderately severe Alzheimer's disease in patients who are already taking memantine and donepezil.
Estonian: 18. oktoobril 2012 avaldas inimravimite komitee negatiivse arvamuse, soovitades keelduda Acrescenti müügiloa andmisest.
English: The effects of Acrescent were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Acrescenti toimet muude katsetega.
English: Changes in the way glutamate transmits signals within the brain have been linked to the memory loss seen in Alzheimer's disease, and over-activity of the NMDA receptors can result in cell damage or death.
Estonian: Alzheimeri tõve korral täheldatud mälukaotust on seostatud muudatustega viisis, kuidas glutamaat edastab ajus signaale.
English: Donepezil works by blocking the action of an enzyme which normally breaks down a neurotransmitter called acetylcholine.
Estonian: Donepesiili toime seisneb neurotransmitterit atsetüülkoliini lagundava ensüümi blokeerimises.
English: It is authorised to treat patients with mild to moderately severe forms of Alzheimer's disease.
Estonian: Donepesiil on näidustatud kerge kuni mõõdukalt raske Alzheimeri tõvega patsientide raviks.
English: It is authorised to treat patients with moderate to severe forms of Alzheimer's disease.
Estonian: Memantiin on näidustatud mõõduka kuni raske Alzheimeri tõvega patsientide raviks.
English: Acetylcholine levels are lower in people suffering from dementia in Alzheimer's disease.
Estonian: Alzheimeri tõvega kaasuva dementsiaga patsientidel on atsetüülkoliini sisaldus veres väike.
English: This will help protect them against the disease.
Estonian: See aitab kaitsta looma haiguse eest.
English: This summary was last updated in September 2015.
Estonian: Kokkuvõtte viimane uuendus: 09-2015.
English: The European Commission granted a marketing authorisation valid throughout the EU for Zulvac SBV on 6 February 2015.
Estonian: Euroopa Komisjon andis Zulvac SBV müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 6. Veebruaril 2015.
English: The full EPAR for Zulvac SBV can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Zulvac SBV kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: Schmallenberg virus vaccine (inactivated)
Estonian: Schmallenbergi viiruse vaktsiin (inaktiveeritud)
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Zulvac SBV's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Veterinaarravimite komitee järeldas, et Zulvac SBV kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas vaktsiini kasutamise Euroopa Liidus heaks kiita.
English: The animals were vaccinated according to the vaccination schedule and were then exposed to the Schmallenberg virus.
Estonian: Loomi vaktsineeriti vaktsineerimiskava kohaselt ning seejärel oli neil kokkupuude Schmallenbergi viirusega.
English: Zulvac SBV is a veterinary vaccine used to protect cattle and sheep from 3.5 months of age against Schmallenberg virus by reducing viraemia (presence of virus in the blood).
Estonian: Zulvac SBV on veterinaarvaktsiin, mida kasutatakse vähemalt 3,5 kuu vanuste veiste ja lammaste kaitsmiseks Schmallenbergi viiruse eest, vähendades vireemiat (viiruse esinemist veres).
English: Zulvac SBV contains Schmallenberg virus that has been inactivated so that it cannot cause disease.
Estonian: Zulvac SBV sisaldab Schmallenbergi viirust, mis on inaktiveeritud ega suuda seetõttu haigust tekitada.
English: The withdrawal period for meat from cattle and sheep treated with Zulvac SBV is ‘zero' days, which means there is no mandatory waiting time.
Estonian: Vaktsiiniga Zulvac SBV vaktsineeritud veiste ja lammaste liha keeluaeg on 0 päeva, mis tähendab, et keeluaega ei ole.
English: Zulvac SBV contains the active substance inactivated (killed) Schmallenberg virus strain BH80/11-4.
Estonian: Zulvac SBV sisaldab toimeainena Schmallenbergi viiruse inaktiveeritud tüve BH80/11-4.
English: Schmallenberg virus is transmitted by midges and causes stillbirths and birth defects in cattle and sheep.
Estonian: Schmallenbergi viirust levitavad teatud habesääsklased ning see põhjustab veistel ja lammastel surnultsünde ja sünnikahjustusi.
English: In the future if the animals are exposed to Schmallenberg virus, the immune system will be able to produce antibodies more quickly.
Estonian: Kui loomad puutuvad Schmallenbergi viirusega hiljem uuesti kokku, tekivad antikehad kiiremini.
English: The effectiveness of Zulvac SBV has been investigated in laboratory studies in cattle and sheep.
Estonian: Zulvac SBV efektiivsust veistel ja lammastel on uuritud laboriuuringutes.
English: When it is given to cattle or sheep, the animals' immune system recognises the virus as foreign and makes antibodies against it.
Estonian: Kui veisele või lambale manustatakse vaktsiini, peab looma immuunsüsteem viirust võõraks ja tekitab selle vastu antikehi.
English: This is a summary of the European public assessment report (EPAR) for Zulvac SBV.
Estonian: See on vaktsiini Zulvac SBV Euroopa avaliku hindamisaruande kokkuvõte.
English: In cattle protection starts two weeks after vaccination and lasts 12 months.
Estonian: Veistel tekib kaitse 2 nädalat pärast vaktsineerimist ning kestab 12 kuud.
English: For practical information about using Zulvac SBV, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Estonian: Kui loomaomanikud või -pidajad vajavad Zulvac SBV kasutamise praktilisi nõuandeid, peavad nad lugema pakendi infolehte või pöörduma oma veterinaararsti või apteekri poole.
English: In sheep protection starts three weeks after vaccination and lasts six months.
Estonian: Lammastel tekib kaitse 3 nädalat pärast vaktsineerimist ning kestab 6 kuud.
English: Zulvac SBV is a vaccine.
Estonian: Zulvac SBV on vaktsiin.
English: The vaccine is given to cattle as two injections of 2 ml into the neck muscle three weeks apart and to sheep as a single injection of 1 ml under the skin behind the elbow.
Estonian: Vaktsiini manustatakse veistele kahe 2 ml süstina kaelalihasesse kolmenädalase vahega ja lammastele ühe 1 ml subkutaanse süstina küünarliigese taha.
English: What is Zulvac SBV and what is it used for?
Estonian: Mis on Zulvac SBV ja milleks seda kasutatakse?
English: In pregnant ewes vaccination reduced viraemia and infection of the embryo.
Estonian: Tiinetel uttedel vähendas vaktsineerimine vireemiat ja loote nakatumist.
English: It is not intended to provide practical advice on how to use Zulvac SBV.
Estonian: Hindamisaruandes ei anta Zulvac SBV kasutamise praktilisi nõuandeid.
English: For female sheep vaccination should be at least two weeks before breeding to reduce viraemia (virus in the blood) and infection of the embryo during the first trimester of pregnancy.
Estonian: Uttede vaktsineerimine peab toimuma vähemalt kaks nädalat enne paaritamist, et vähendada vireemiat ja loote nakatumist tiinuse esimesel trimestril.
English: Why is Zulvac SBV approved?
Estonian: Miks Zulvac SBV heaks kiideti?
English: For booster vaccination in non-breeding sheep a single injection of 1 ml should be given every six months whilst in female breeding sheep a single injection of 1 ml should be given at least two weeks before breeding.
Estonian: Kordusvaktsineerimisel tuleb muudele kui sugulammastele teha üks 1 ml süst iga 6 kuu järel; suguuttedele tuleb teha üks 1 ml süst vähemalt 2 nädalat enne paaritamist.
English: In sheep more than one in ten animals may have an increase in body temperature of up to 1.5 °C during the 24 hours after vaccination.
Estonian: Lammastel võib enam kui 1 loomal 10st tõusta kehatemperatuur kuni 1,5 °C võrra 24 tunni jooksul pärast vaktsineerimist.
English: For booster vaccination in cattle two injections of 2 ml should be given three weeks apart every 12 months.
Estonian: Kordusvaktsineerimisel tuleb veistele teha kaks 2 ml süsti kolmenädalase vahega iga 12 kuu järel.
English: Other information about Zulvac SBV:
Estonian: Muu teave Zulvac SBV kohta
English: In pregnant ewes more than one in ten animals may have an increase in body temperature of up to 0.8 °C during 4 hours after vaccination.
Estonian: Tiinetel uttedel võib enam kui 1 loomal 10st tõusta kehatemperatuur kuni 0,8 °C võrra 4 tunni jooksul pärast vaktsineerimist.
English: What are the risks associated with Zulvac SBV?
Estonian: Mis riskid Zulvac SBV-ga kaasnevad?
English: The main measure of effectiveness was absence of viraemia following exposure to the virus.The studies showed that Zulvac SBV protects cattle two weeks and sheep three weeks after vaccination.
Estonian: Uuringud näitasid, et Zulvac SBV kaitse algab veistel 2 nädalat ja lammastel 3 nädalat pärast vaktsineerimist.
English: How does Zulvac SBV work?
Estonian: Kuidas Zulvac SBV toimib?
English: More than one in ten animals may show swellings or lumps of up to 8 cm in diameter under the skin at the injection site, which may last for at least 97 days as granules less than 0.5 cm in diameter.
Estonian: Enam kui 1 loomal 10st võivad süstekohal tekkida kuni 8 cm läbimõõduga tursed või nahaalused mügarad, mis võivad alla 0,5 cm läbimõõduga mügaratena püsida vähemalt 97 päeva.
English: How is Zulvac SBV used?
Estonian: Kuidas Zulvac SBV-d kasutatakse?
English: More than one in ten animals may show swellings or lumps of up to 8 cm in diameter under the skin at the injection site, and swellings less than 2 cm in diameter may last for at least 47 days.
Estonian: Enam kui 1 loomal 10st võivad süstekohal tekkida kuni 8 cm läbimõõduga tursed või nahaalused mügarad, mis võivad alla 2 cm läbimõõduga tursetena püsida vähemalt 47 päeva.
English: Zulvac SBV is available as a suspension for injection and can only be obtained with a prescription.
Estonian: Zulvac SBV-d turustatakse süstesuspensioonina ja see on retseptivaktsiin.
English: What benefits of Zulvac SBV have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Zulvac SBV kasulikkus?
English: In cattle, an increase in body temperature of up to 1.5°C during the 48 hours after vaccination and the appearance of small lumps of up to 0.7 cm in diameter at the vaccination site that resolve within 10 days are very common (seen in more than 1 animal in 10).
Estonian: Veistel võib väga sageli (esinenud enam kui 1 loomal 10st) tõusta kehatemperatuur kuni 1,5°C võrra 48 tunni jooksul pärast vaktsineerimist ning vaktsineerimiskohale võivad tekkida väikesed kuni 0,7 cm läbimõõduga mügarad, mis kaovad 10 päeva jooksul.
English: 27 January 2011
Estonian: 27 jaanuar 2011
English: The European Commission issued a decision on 27 January 2011.
Estonian: Euroopa Komisjon tegi otsuse 27. jaanuaril 2011.